Careers  |  Sign In  |  Register

Two Drugs Found to Slow Decline in Lung Disease Patients

The New York Times reports on two studies published in NEJM that have looked at two different drugs that may help slow the decline of people with fatal lung disease. The first study tested the effect of perfenidone, made by InterMune, on patients with idiopathic pulmonary fibrosis while the second study looked at Boehringer Ingelheim‘s drug, nintedanib. Researchers found that “patients taking either drug had significantly smaller drops in lung function than those taking placebos.” The findings are a “major breakthrough” for patients who, until now, had no options other than to take drugs that suppress coughing. “Neither of the drugs has been approved by the Food and Drug Administration. The data from the studies will be submitted to the agency as part of the process of seeking approval for the drugs.”

Read it in The New York Times.

Read the first study in NEJM.

Read the second study in NEJM.